Manufacturers should treat device trust as a design requirement, not a post-launch fix. That means building in authenticated connections, encryption, role-bound access controls, and security testing during planning, verification, and validation so the device ships with a governed trust model rather than an assumed one.
How should manufacturers build security into connected medical devices before release?
Manufacturers should treat connected-device trust as part of the product design, not a post-launch patch. That means authenticated connections, encryption, role-bound access controls, and security testing must be built into planning, verification, and validation so the device ships with a governed trust model rather than an assumed one.
What “secure before release” really means for connected medical devices
For connected medical device, “secure before release” means the device can prove what it is, communicate over protected channels, and limit what each user, service, or update path can do. The security model should cover the device from onboarding through operation, maintenance, and decommissioning, because weaknesses at any stage can become patient-safety and operational issues after deployment.
That also means manufacturers should design for realistic clinical use. Devices often move between networks, facilities, and support teams, so security controls have to survive configuration drift, shared environments, and long service lives. If the trust model is fragile in the lab, it will usually fail faster in the field.
Which controls matter most before the device ships?
The most important controls are device identity, authenticated communication, least-privilege access, secure update paths, and integrity testing. A connected medical device should not rely on default credentials, implicit trust in the local network, or unauthenticated device commands. Instead, the manufacturer should establish secure onboarding, certificate-based or otherwise strong authentication, encrypted transport, and clear separation between operator, maintainer, and administrative functions.
Release readiness also depends on whether the device can be updated safely. Firmware, configuration, and software updates should be signed, verified, and revocable where possible. If a device cannot validate what it accepts, then compromise of the supply chain, service channel, or management interface can become a durable foothold.
For device identity and onboarding patterns, the Device and IoT Identity Guide is a useful reference for strong device identity, attestation, and lifecycle trust. For healthcare-specific access and device context, Healthcare Identity Security Guide covers medical devices alongside clinician access and shared clinical environments.
How should manufacturers verify the control model before release?
Verification should prove that the device behaves securely under normal, misconfigured, and hostile conditions. That includes testing authentication boundaries, access enforcement, update validation, encryption in transit, and failure handling when dependencies are unavailable or untrusted. Security testing should also include code review, interface testing, and negative testing for unauthorized commands, weak defaults, and downgrade or replay conditions.
Manufacturers should treat evidence as part of release engineering. If a control cannot be shown to work through test results, configuration evidence, or validation records, it should not be assumed to work just because it was specified. This is especially important for devices that may be integrated into hospital networks where procurement, clinical engineering, and IT all depend on the manufacturer’s stated security posture.
For general hardening and baseline discipline, CIS Benchmarks are useful where the device includes supported operating-system or platform components. For broader control discipline around identification, authentication, and configuration management, NIST SP 800-53 Rev 5 Security and Privacy Controls provides a strong control catalog. NIST SP 800-207 Zero Trust Architecture is also relevant where the device must continuously verify access rather than trust the surrounding network.
Risk and Threat Considerations
Connected medical devices are attractive targets because they combine persistent connectivity, high trust, and long lifecycles. Weak onboarding, weak authentication, or permissive management access can expose a device to unauthorized commands, tampering, or lateral movement into adjacent clinical systems. In healthcare settings, the risk is not just device compromise, it is also workflow disruption and potential patient-safety impact.
Failure mechanism: Default credentials, unmanaged secrets, weak device identity, or unencrypted management channels let an attacker impersonate a legitimate operator, intercept traffic, or reuse trusted access after deployment.
Impact: The attacker can change device settings, interfere with treatment workflows, exfiltrate data, or use the device as a foothold into the broader clinical environment.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST SP 800-53 Rev 5 and CIS Controls v8 set the technical controls, while ISO/IEC 27001:2022 defines the regulatory obligations.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST SP 800-53 Rev 5 | IA-9 — Identification and Authentication (Non-Organizational Users) | Connected medical devices authenticate to remote services and management endpoints. |
| IA-5 — Authenticator Management | Pre-release security depends on controlling device credentials, certificates, and rotation. | |
| CM-3 — Configuration Change Control | Release security depends on controlled baselines for shipped device settings and updates. | |
| Recommendation — Require mutual authentication for device and service connections. Manage device credentials with rotation, protection, and revocation controls. Enforce approved configuration baselines before shipment. | ||
| ISO/IEC 27001:2022 | A.8.9 — Configuration management | Shipped device trust depends on controlled and verified secure configuration. |
| Recommendation — Establish secure configuration baselines for device builds and releases. | ||
| CIS Controls v8 | CIS-4 — Secure Configuration of Enterprise Assets and Software | Connected devices need hardened defaults and verified secure settings before deployment. |
| Recommendation — Harden device defaults and validate secure configuration before release. | ||
Practitioner Guidance
What to prioritise: Start with the device trust boundary, not the user interface. If a device can accept commands, updates, or remote support actions, those pathways need explicit authentication, authorization, and test evidence before release.
What to verify: Require proof that identity, encryption, and update validation work on the shipped build, not only in development. Confirm that defaults are disabled, roles are separated, and insecure fallback modes are either removed or tightly constrained.
Decision rule: If a feature can affect patient-facing behaviour, clinical data, or remote administration, it should ship only when the access path is observable, bounded, and revocable. Treat any exception as a release risk that needs named ownership and compensating controls.
Practitioner takeaway: The release question is not whether the device is connected, but whether every trusted action has a verifiable identity, a narrow privilege boundary, and a testable control story.
Related resources from NHI Mgmt Group
- How should healthcare security teams secure connected medical devices without disrupting clinical operations?
- How should healthcare organisations use digital certificates to secure connected medical devices?
- How should healthcare teams secure connected medical devices across large IoMT environments?
- How should organisations secure connected devices during manufacturing before they are deployed in the field?